Skip to main content
S&P 5007,735.41+0.16%DOW50,930.91-0.48%NASDAQ27,323.65+0.49%BTC$86,429.00+1.41%ETH$2,722.61+0.88%GOLD$4,167.90+0.13%OIL$89.78-1.46%
Smart Investors Daily
SID Premium
GSK plc logo

NASDAQ · GSK

GSK plc

Healthcare · Drug Manufacturers - General

$47.03

Down-$0.47 (-0.99%)

Updated Oct 5, 2026, 2:02 PM

SID Score

5.8/10

Composite research score

Smart Money

56/100

Neutral

Market cap
99.39B
P/E ratio
13.41
Dividend yield
3.56%
52-week range
$42.85 – $61.70
Volume
5.39M
Avg. volume
5.18M

Price performance · GSK

GSK price history

1M range · 19 trading sessions · Daily adjusted prices

Prices through Oct 2, 2026

GSK closed at $47.03 after 19 trading sessions, down 3.11% for the selected period.

Last close
$47.03
Period change
-3.11%
Period low
$47.03
Period high
$51.08
Daily close
View OHLC price history
GSK OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 2, 2026$47.08$47.16$46.84$47.035.39M
Oct 1, 2026$48.16$48.23$47.13$47.187.9M
Sep 30, 2026$48.925$49.05$48.17$48.175.85M
Sep 29, 2026$49.405$49.82$48.9623$49.352.89M
Sep 28, 2026$49.17$49.80$48.98$49.703.59M
Sep 25, 2026$49.49$49.495$49.00$49.243.32M
Sep 24, 2026$49.59$50.1395$49.565$49.652.84M
Sep 23, 2026$50.18$50.74$49.67$49.713.04M
Sep 22, 2026$50.69$50.99$50.22$50.724.3M
Sep 21, 2026$50.75$51.32$50.46$51.082.87M
Sep 18, 2026$50.20$50.33$49.50$50.224.71M
Sep 17, 2026$50.72$51.075$50.62$51.063.08M
Sep 16, 2026$50.19$50.71$50.055$50.292.84M
Sep 15, 2026$49.69$50.155$49.63$50.012.74M
Sep 14, 2026$50.29$50.30$49.61$50.053M
Sep 11, 2026$48.70$48.80$47.85$48.132.28M
Sep 10, 2026$48.47$48.59$47.975$48.122.15M
Sep 9, 2026$48.815$49.16$48.60$48.632.41M
Sep 8, 2026$49.00$49.2349$48.54$48.543.06M

Latest GSK news

The latest Smart Investors Daily articles mentioning GSK.

Stock researchCompany · Overview

GSK research

Overview

Company profile and research snapshot.

Company profile

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$53.00
Implied upside
—
Analysts
7
GSK recent ratings
DateFirmRatingTarget
Jun 8, 2026DeutscheHold—
May 28, 2026JefferiesBuy—
May 27, 2026DeutscheHold—
May 6, 2026DeutscheHold—
May 6, 2026CitigroupNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 30, 2026

GSK (LSE:GSK) The Latest Update Raises A Bigger Question

Fresh funding from the Gates Foundation for AN2 Therapeutics’ tuberculosis collaboration with GSK (LSE:GSK) has put the pharma group’s boron based LeuRS inhibitor program back in focus for investors. The GSK share price has softened in the very short term, with a 1-day share price return of a 0.22% decline and a 7-day share price return of a 2.62% decline, even as fresh R&D headlines such as the Gates backed TB work and recent conference appearances keep the pipeline in view. Yet momentum...

Yahoo · Sep 30, 2026

Hatteras Venture Partners Names Sir Andrew Witty as Chairman and Ned Sharpless, M.D., as Managing Director of Hatteras Discovery Innovation, Expanding Proven Investment Strategies

– Hatteras holds first closing of Hatteras Opportunity Fund II (HOF II) – – HOF II closing brings capital under management to over $1 billion – DURHAM, N.C., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Hatteras Venture Partners, a venture capital firm focused on transformative healthcare innovation, has appointed two longtime healthcare leaders to senior roles as it builds its next generation of companies and expands support for later-stage portfolio businesses. Sir Andrew Witty, former Chief Executive O

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By